All terms
Health Technology Assessment
Systematic evaluation of clinical and economic value of a health technology.
Reviewed by Christian Espinosa, Founder, Blue Goat CyberLast reviewed May 5, 2026
Definition
HTA bodies evaluate the clinical effectiveness, safety, and cost-effectiveness of medical technologies to inform coverage and pricing - NICE (UK), HAS (France), G-BA/IQWiG (Germany), CADTH (Canada), and the new EU Joint Clinical Assessment (JCA). What the regulation says
Health Technology Assessment (HTA) bodies like those referenced by the EU HTA Regulation (Regulation (EU) 2021/2282) play a crucial role in evaluating new and existing medical devices. These bodies consider clinical efficacy, safety, and cost effectiveness to inform national reimbursement and market access decisions. While not a direct regulatory approval step, a positive HTA outcome is often a prerequisite for widespread adoption and reimbursement within a healthcare system.What this means in practice
Outside the U.S., HTA decisions often gate market access. EU JCA (effective 2025) creates a single clinical assessment across member states for high-risk devices and IVDs.Examples
- A manufacturer of a novel orthopedic implant conducts a post-market clinical study to gather real-world effectiveness and cost utility data specifically for submission to Germany's G-BA.
- A diagnostic company developing a new in vitro diagnostic (IVD) test includes health economic endpoints in its clinical trial design to satisfy anticipated requirements from national HTA agencies.
- Before launching a new surgical robot in Canada, a MedTech company engages with CADTH to understand their evidence expectations for demonstrating value and securing reimbursement.
Common pitfalls
- •Misunderstanding HTA as a regulatory approval process, rather than a reimbursement and market access gate.
- •Failing to consider HTA requirements early in product development, leading to late-stage data collection challenges.
- •Underestimating the data requirements for HTA submissions, which often go beyond basic regulatory clinical evidence.
- •Assuming that a device approved in one jurisdiction will automatically receive favorable HTA outcomes in others.
- •Neglecting to engage with HTA bodies or experts during the clinical development planning phase.
Frequently asked questions
Regulatory approval (e.g., FDA clearance, CE Mark) focuses on ensuring a device is safe and effective for its intended use. HTA assesses the added value, cost-effectiveness, and real-world impact of a device to inform decisions about public funding and adoption.
Cross-references
See also
Related terms
Shared paths + categoryReimbursement
Joint Clinical Assessment(JCA)
EU-wide clinical assessment of high-risk medical devices and IVDs.
Same category
Reimbursement
Quality-Adjusted Life Year(QALY)
Outcome metric combining length and quality of life used in HTA.
Same category
Reimbursement
Budget Impact Model(BIM)
Financial model that estimates the total cost consequences of adopting a new technology to a payer's budget over a defined horizon.
Reimbursement & Market Access · adjacent
Reimbursement
Prior Authorization
Payer requirement for approval before a service or device is covered.
Reimbursement & Market Access · adjacent
Reimbursement
CPT Codes(CPT)
AMA-maintained codes that describe medical procedures and services.
Reimbursement & Market Access
Reimbursement
Current Procedural Terminology Codes(CPT)
AMA-maintained codes used to report medical procedures and services for billing.
Reimbursement & Market Access
Latest in MedTech
Primary references
3 sourcesLink health: 3 verified· last checked 2026-06-20
INAHTA·1AdvaMed·1AMA·1
- 1INAHTAVerifiedINAHTAinahta.org
- 2AdvaMed - Payment & CoverageVerifiedAdvaMedadvamed.org
- 3AMA CPT ResourcesVerifiedAMAama-assn.org
Inline markers like [1] jump to the matching reference above.